NCT00338884View on ClinicalTrials.gov

Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sunitinib malate

Sunitinib malate starting dose 37.5 mg daily continuous daily schedule

Trial Locations (15)

112

Pfizer Investigational Site, Taipei

407

Pfizer Investigational Site, Taichung

710

Pfizer Investigational Site, Tainan City

1431

Pfizer Investigational Site, Buenos Aires

3165

Pfizer Investigational Site, East Bentleigh

3168

Pfizer Investigational Site, Clayton

5000

Pfizer Investigational Site, Adelaide

44280

Pfizer Investigational Site, Guadalajara

64460

Pfizer Investigational Site, Monterrey

X5000AAI

Pfizer Investigational Site, Córdoba

(2000)

Pfizer Investigational Site, Rosario

90610-000

Pfizer Investigational Site, Porto Alegre

01308-050

Pfizer Investigational Site, São Paulo

110-744

Pfizer Investigational Site, Seoul

120-752

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00338884 - Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer | Biotech Hunter | Biotech Hunter